Eli Lilly announced that it will delay most new clinical trials and pause enrollment in most ongoing studies but will continue ongoing clinical trials for patients who are already enrolled.

By delaying most new study starts and pausing enrollment of new patients or healthy volunteers in most ongoing studies, the company hopes to “ease the burden on participating healthcare facilities,” said Lilly’s chief medical officer Tim Garnett.

Study participants currently enrolled in Lilly clinical trials should continue following study protocols and are encouraged to speak with their physician if they have any concerns, the company said.